Trial record 9 of 28 for:    "desmoid tumor"

Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor

This study is ongoing, but not recruiting participants.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Children's Oncology Group Identifier:
First received: September 10, 2003
Last updated: March 21, 2016
Last verified: March 2016
This phase II trial is studying how well giving sulindac together with tamoxifen works in treating patients with desmoid tumor. Sulindac may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Hormone therapy using tamoxifen may fight cancer by blocking the use of estrogen. Combining sulindac with tamoxifen may kill more cancer cells.

Condition Intervention Phase
Desmoid Tumor
Drug: tamoxifen citrate
Drug: sulindac
Other: laboratory biomarker analysis
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Study of Sulindac and Tamoxifen in Patients With Desmoid Tumors That Are Recurrent or Not Amenable to Standard Therapy

Resource links provided by NLM:

Further study details as provided by Children's Oncology Group:

Primary Outcome Measures:
  • Event-free Survival [ Time Frame: Study enrollment until time of disease progression or death as a first event (maximum follow-up 5 years) ] [ Designated as safety issue: No ]
    Two-year event-free survival (EFS). Events include disease progression (increase in the greatest product of 2 perpendicular diameters of any lesion by > 25% or new biopsy-proven lesions), and death in absence of disease progression. Reported as Kaplan-Meier estimate of two-year EFS proportion.

Secondary Outcome Measures:
  • Toxicity as Assessed by the National Cancer Institute Common Toxicity Terminology for Adverse Events v3.0 [ Time Frame: Up to 12 months ] [ Designated as safety issue: Yes ]
  • Tumor Response Rate According to Response Evaluation Criteria in Solid Tumors (RECIST) [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]
  • Changes in Magnetic Resonance Imaging (MRI) Signal Features [ Time Frame: From baseline to up to 5 years ] [ Designated as safety issue: No ]
    MRI must include images in at least two planes with (a) pre-contrast images with the following pulse sequences T-1 weighted, fast spin echo T-2 weighted with fat saturation, and a short tau inversion recovery (STIR); and (b) post-contrast images with T-1 weighted pulse sequence with fat suppression.

Enrollment: 70
Study Start Date: February 2004
Primary Completion Date: August 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment (enzyme inhibitor therapy, anti-estrogen therapy)
Patients receive oral sulindac and oral tamoxifen citrate twice daily for up to 12 months (four 3-month courses) in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) receive 1 additional month of treatment beyond documentation of CR.
Drug: tamoxifen citrate
Given orally
Other Names:
  • Nolvadex
  • TAM
  • tamoxifen
  • TMX
Drug: sulindac
Given orally
Other Names:
  • Aflodac
  • Algocetil
  • Clinoril
Other: laboratory biomarker analysis
Correlative studies

Detailed Description:


I. Determine the progression-free survival of patients with desmoid tumor that is recurrent or not amenable to standard therapy treated with sulindac and tamoxifen.

II. Determine the safety and efficacy of this regimen, in terms of event-free survival, of these patients.


I. Determine the tumor response rate in patients treated with this regimen.

II. Correlate changes in Magnetic Resonance Imaging (MRI) signal features of the tumor with clinical outcome in patients treated with this regimen.

III. Correlate pathological studies of cyclooxygenase-2 (COX-2) and estrogen/progesterone receptor expression in the tumor with clinical outcome in patients treated with this regimen.

IV. Collect information about clinical factors that make a tumor unresectable at diagnosis and resectable during the four courses of study treatment.

V. Determine whether short-term endocrine toxicity is associated with treatment with this regimen in these patients.

OUTLINE: This is a multicenter study.

Patients receive oral sulindac and oral tamoxifen twice daily for up to 12 months (four 3-month courses) in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) receive 1 additional month of treatment beyond documentation of CR.

After completion of study treatment, patients are followed for 5 years.


Ages Eligible for Study:   up to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed desmoid tumor, meeting 1 of the following criteria:

    • Newly diagnosed disease

      • Not previously treated
      • Not amenable to complete surgical resection and/or radiotherapy

        • If surgical resection was attempted, there must be gross residual disease measurable by MRI
    • Radiographically documented recurrent or progressive disease

      • No prior chemotherapy or radiotherapy for the present recurrence

        • Tumors that progressed on prior chemotherapy are allowed provided patients have not received chemotherapy for this recurrence
  • Measurable disease by gadolinium-enhanced MRI
  • No other fibroblastic lesions or fibromatoses

    • Lipofibromatosis or desmoplastic fibroma of the bone allowed
  • Performance status - Karnofsky Score 50-100% (patients over age 16)
  • Performance status - Lansky Score 50-100% (patients age 16 and under)
  • At least 8 weeks
  • Absolute neutrophil count at least 1,000/mm^3
  • Platelet count at least 100,000/mm^3 (transfusion independent)
  • Hemoglobin at least 10.0 g/dL (transfusion allowed)
  • No hemophilia
  • No von Willebrand disease
  • No other clinically significant bleeding diathesis
  • Bilirubin no greater than 1.5 times upper limit of normal (ULN)
  • Alanine aminotransferase (ALT) less than 2.5 times ULN
  • Creatinine adjusted according to age as follows:

    • No greater than 0.4 mg/dL (≤ 5 months)
    • No greater than 0.5 mg/dL (6 months -11 months)
    • No greater than 0.6 mg/dL (1 year-23 months)
    • No greater than 0.8 mg/dL (2 years-5 years)
    • No greater than 1.0 mg/dL (6 years-9 years)
    • No greater than 1.2 mg/dL (10 years-12 years)
    • No greater than 1.4 mg/dL (13 years and over [female])
    • No greater than 1.5 mg/dL (13 years to 15 years [male])
    • No greater than 1.7 mg/dL (16 years and over [male])
  • Creatinine clearance or radioisotope glomerular filtration rate at least 70 mL/min
  • No prior deep venous thrombosis
  • Electrocardiogram (EKG) normal
  • Chest x-ray normal
  • No prior significant gastrointestinal hemorrhage
  • No prior peptic ulcer disease
  • Not pregnant or nursing
  • Fertile patients must use effective nonhormonal contraception
  • No evidence of active graft-versus-host disease
  • No allergy to aspirin
  • Recovered from prior immunotherapy
  • At least 7 days since prior anticancer biologic agents
  • At least 6 months since prior allogeneic stem cell transplantation
  • More than 1 week since prior growth factors
  • No concurrent immunomodulating agents
  • No prior nonsteroidal anti-inflammatory drugs (NSAIDs) for desmoid tumor
  • More than 2 weeks since prior myelosuppressive chemotherapy (4 weeks for nitrosoureas) and recovered
  • No concurrent anticancer chemotherapy
  • No prior estrogen antagonists for desmoid tumor
  • No concurrent hormonal contraceptives
  • No concurrent steroids except for non tumor indications (e.g., asthma or severe allergic reactions)
  • No concurrent NSAIDs for desmoid tumor

    • Occasional NSAIDs for musculoskeletal or other pain are allowed
  • Recovered from prior radiotherapy
  • No concurrent adjuvant radiotherapy
  • No concurrent participation in another COG therapeutic study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00068419

United States, California
Children's Oncology Group
Monrovia, California, United States, 91016
Sponsors and Collaborators
Children's Oncology Group
National Cancer Institute (NCI)
Principal Investigator: Stephen Skapek, MD Children's Oncology Group
  More Information

Responsible Party: Children's Oncology Group Identifier: NCT00068419     History of Changes
Other Study ID Numbers: ARST0321  NCI-2009-00424  CDR0000322260  COG-ARST0321  U10CA098543 
Study First Received: September 10, 2003
Results First Received: October 7, 2013
Last Updated: March 21, 2016
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Fibromatosis, Aggressive
Neoplasms by Histologic Type
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms, Fibrous Tissue
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Antirheumatic Agents
Bone Density Conservation Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Estrogen Antagonists
Estrogen Receptor Modulators
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Physiological Effects of Drugs
Selective Estrogen Receptor Modulators
Sensory System Agents processed this record on May 26, 2016